Join
Live feed
·
INSIDERFilingvia Quantisnow
Keros Therapeutics Inc. logo

Director Farzan Nima was granted 5,250 shares (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
KROS· Keros Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KROS (Keros Therapeutics Inc.) and more on Quantisnow.